Difference between revisions of "Panobinostat (Farydak)"
(FDA approval) |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Acute myeloid leukemia]] | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
*[[Waldenström macroglobulinemia]] | *[[Waldenström macroglobulinemia]] | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 20: | Line 15: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *2/23/2015: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435296.htm FDA accelerated approval] "for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent." | + | *2/23/2015: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435296.htm FDA accelerated approval] "for the treatment of patients with [[Multiple myeloma|multiple myeloma]] who have received at least 2 prior regimens, including [[Bortezomib (Velcade)|bortezomib]] and an [[:Category:Immunomodulatory_drugs_(IMiDs)|immunomodulatory agent]]." |
==Also known as== | ==Also known as== | ||
| Line 33: | Line 28: | ||
[[Category:HDAC inhibitors]] | [[Category:HDAC inhibitors]] | ||
| + | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:Waldenström macroglobulinemia medications]] | [[Category:Waldenström macroglobulinemia medications]] | ||
[[Category:Drugs FDA approved in 2015]] | [[Category:Drugs FDA approved in 2015]] | ||
Revision as of 18:45, 5 October 2015
General information
Class/mechanism: Pan-histone deacetylase (HDAC) inhibitor, or HDACi. Inhibition of histone deacetylases results in hyperacetylation of histones and modulates gene expression by creating an open chromatin state that leads to expression of previously silenced genes. This modulation has been observed to be associated with decreased expression of oncogenes such as Bcr-Abl and HER-2, induction of cell cycle arrest, promotion of apoptosis, and decreased invasion of tumor cells.[1][2][3][4][5]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2/23/2015: FDA accelerated approval "for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent."
Also known as
LBH589
References
- ↑ 1.0 1.1 1.2 Panobinostat (Farydak) package insert
- ↑ Panobinostat (Farydak) package insert, locally hosted backup
- ↑ Novartis's information about panobinostat
- ↑ Hasegawa H, Yamada Y, Tsukasaki K, Mori N, Tsuruda K, Sasaki D, Usui T, Osaka A, Atogami S, Ishikawa C, Machijima Y, Sawada S, Hayashi T, Miyazaki Y, Kamihira S. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. Leukemia. 2011 Apr;25(4):575-87. Epub 2011 Jan 18. link to original article PubMed
- ↑ Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD, Albelda SM. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009 Aug;8(8):2221-31. Epub 2009 Aug 11. link to original article PubMed